United States: Capitol Hill Healthcare Update - March 27, 2017

AHCA Autopsy: What Happened, What's Next?

House Speaker Paul Ryan's decision to cancel Friday's vote on the American Health Care Act triggered post-mortem jockeying among vying GOP factions struggling to come to grips with how the party failed to repeal a law it has singularly campaigned against for the last seven years. Republicans' inability to muster a majority of their 237 House members to back Ryan's plan was the result of a combination of factors, including the evolving policy demands of conservative lawmakers as well as the powerlessness of congressional leaders and the White House to persuade the rank and file to stay in line.

Just five months ago, President Trump ran up huge winning margins in most of the congressional districts represented by conservatives, including the 30-member House Freedom Caucus. Those conservatives once feared Trump; they openly fretted about how a single Trump tweet could roil their voters. But during a White House meeting last week, conservatives defied Trump's call to support the bill and instead proposed a series of ever-changing policy demands. They wanted to jettison the 10 essential health benefits the Affordable Care Act (ACA) requires insurers to include in all plans, which conservatives believe are market-distorting mandates that are causing prices to skyrocket. Trump agreed to drop them. But conservatives had more demands, including allowing insurers to charge different premiums based on age, gender and pre-existing health condition.

Ending those policies on community rating and guaranteed issue would have undercut the bill's support from moderate Republicans, who were already distraught over separate Medicaid changes and were backing away from the legislation. Trump denied the Freedom Caucus's last demand, and the group couldn't accept what otherwise would have been seemingly historic conservative policy victories ending most of the ACA and its mandates, repealing nearly $1 trillion in ACA taxes, and overhauling Medicaid.

Can the GOP's plans to repeal the ACA be resurrected? At least in the short term, probably not. Trump and Ryan are signaling that they are pivoting to budget issues and tax reform. Procedurally, the reconciliation legislation that Republicans were using to repeal the ACA will expire as soon as Congress authorizes a new fiscal 2018 reconciliation bill, which GOP leaders plan to use for tax reform. Without the procedural protections of the reconciliation bill, which can't be filibustered in the Senate, Republicans would be forced to persuade at least eight Senate Democrats to vote for any ACA-related legislation.

Trump said last week that he's content to sit on the sidelines while the ACA "explodes," especially in the individual market, where insurers are pulling out and premiums are rising. It's not clear whether the U.S. Department of Health and Human Services (HHS) will try to hasten that explosion through rulemakings or instead prop up the individual market while attempting to forge bipartisan fixes with congressional Democrats.

Despite the Republicans' political implosion, legislating on healthcare is far from over. Before fall, Congress must approve new Food and Drug Administration (FDA) user fee agreements with pharmaceutical and medical device manufacturers as well as reauthorize the Children's Health Insurance Program. Trump also said he wants to work with Democrats, including Rep. Elijah Cummings (D-Md.), on bringing down prescription drug costs.

Still, given the Republicans' seven-year campaign against the ACA, Speaker Ryan's statement when he canceled the repeal vote was jarring: "Obamacare is the law of the land. We're going to be living with Obamacare for the foreseeable future."

Price to Testify on Trump's HHS Budget

HHS Secretary Tom Price is expected to face a bipartisan gauntlet Wednesday when he defends before skeptical lawmakers the Trump administration's proposed deep budget cuts for health and medical research programs. The House appropriations subcommittee that funds HHS and its related agencies scheduled a hearing to examine President Trump's fiscal 2018 budget proposal. Price is the only witness.

Trump is calling on Congress to reduce HHS spending by 18 percent, or about $15 billion from the current fiscal 2017 spending level; cut  funding by $5.8 billion; increase industry FDA user fees and cut congressional appropriations for the agency; and shutter the Agency for Healthcare Research and Quality. Democrats have criticized the spending cuts – especially for NIH – but so have Republicans, including Rep. Tom Cole (R-Okla.), who is chairman of the appropriations subcommittee that funds HHS.

Alexander Praises Gottlieb After Meeting

President Trump's nominee to lead the FDA had a positive meeting last week with the senator whose committee is responsible for confirming Dr. Scott Gottlieb to lead the agency. Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) said he had an "excellent meeting" with Gottlieb and declared him "well-qualified to lead the FDA." Alexander said confirmation hearings would be scheduled after Gottlieb completed required Office of Government Ethics paperwork.

Gottlieb has held several positions within the FDA, including as deputy commissioner. In addition to agency experience, Gottlieb has been on the frontlines of healthcare as a physician and a patient. He trained at the Mount Sinai School of Medicine and is a cancer survivor having been successfully treated for Hodgkin's lymphoma.

Gottlieb isn't likely to win widespread bipartisan support. He's generally an advocate of deregulation and has worked at conservative policy think tanks. Some consumer groups and Democrats have already come out against his nomination.

GOP-Led House Panel Probes Drug Prices

A House subcommittee led by conservative Republicans who opposed their party's effort to repeal the ACA held a hearing last week on drug prices, saying pharmaceutical manufacturers are manipulating regulatory safeguards to drive up prices and block generic competitors. Ostensibly to shed light on the pharmaceutical supply chain, the hearing focused on drug prices and how supply chains and FDA safety mechanisms like Risk Evaluation and Mitigation Strategies (REMS) can be used to increase prices and thwart generic competition. Witnesses included an official from the Association for Accessible Medicines (formerly GPhA), a consumer group and a Johns Hopkins University professor critical of branded drug companies.

The House Oversight and Government Reform Subcommittee on Health is chaired by Rep. Jim Jordan (R-Ohio), one of the founders of the conservative Freedom Caucus. The caucus's current chairman, Rep. Mark Meadows (R-N.C.), also is a member of the subcommittee. The top Democrat on the full committee, Rep. Elijah Cummings (D-Md.), also participated in the hearing, criticizing increases in drug prices and companies that he said were hiding behind FDA safety programs like REMS to block entry of generic drugs.

Dr. Janet Woodcock, who leads the FDA's drug center, told the subcommittee that the agency receives 150 complaints annually from generic manufacturers saying they can't gain access to drugs for bioequivalence testing because of REMS.

Draft Bill Would Give FDA Authority Over Lab-Developed Tests

Two House members last week released draft diagnostics reform legislation that would grant the FDA new regulatory authority over the creation and manufacturing of laboratory-developed tests. Reps. Larry Bucshon (R-Ind.) and Diana DeGette (D-Colo.) are seeking stakeholder feedback on their draft bill by April 7. Both lawmakers are senior members of the House Energy and Commerce Committee, which has jurisdiction over the FDA and previously has released related legislation.

Under the draft bill, in vitro clinical tests would have their own FDA regulatory structure separate from that of traditional medical devices. The legislation would also grant the FDA jurisdiction over test development and manufacturing, with the Centers for Medicare and Medicaid Services maintaining oversight of laboratory operations pursuant to the Clinical Laboratory Improvement Amendments (CLIA) law.

It's not currently clear if the draft legislation can be finalized in time to be included with the separate medical device user fee reauthorization, which Congress is aiming to approve by summer.

House Panel Eyes Medical Device User Fees

The House Energy and Commerce Health Subcommittee on Tuesday will hold a hearing on the FDA's medical device user fee program. Dr. Jeff Shuren, who leads FDA's device center, is scheduled to testify. Other scheduled witnesses include Cynthia Bens of the Alliance for Aging Research; Robert Kieval of CVRx, a Minnesota-based device manufacturer; Patrick Daly of Cohera Medical, a North Carolina-based device manufacturer; and Diane Wurzburger of GE Healthcare. The pending medical device user fee proposal builds on sweeping changes enacted under the current agreement, which called for higher industry user fees in return for stepped-up agency performance and review times. The FDA estimates that the industry fees negotiated in the proposed agreement will average $200 million per year.

Sanders, Cummings Demand Company Pricing Details

Two Democratic lawmakers leading the charge on lowering prescription drug prices are calling on New Jersey-based PTC Therapeutics to release information about the price it will charge for its drug to treat Duchenne muscular dystrophy. Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) sent a letter last week to CEO Stuart Peltz after the company purchased the drug, deflazacort, from Marathon Pharmaceuticals. The two lawmakers in February wrote to Marathon after media reports that the company planned to charge $89,000 per year for the treatment, which they say is currently available outside the United States for $1,000. "We urge you to keep the price of this relatively common steroid at its current importation cost," Sanders and Cummings wrote. "Doing so will allow patients to use deflazacort in combination therapies without going into bankruptcy."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.